Empty Capsule Market Valuation Projected to Reach $6.96B by 2036

Got story updates? Submit your updates here. ›

The global empty capsules market is positioned for steady expansion over the next decade, growing from $3.22 billion in 2026 to $6.96 billion by 2036 at an 8.0% compound annual growth rate. This growth is driven by pharmaceutical manufacturers' increasing emphasis on scalable, reliable dosage formats that meet strict quality standards for dimensional consistency, performance during high-speed filling, storage stability, and comprehensive documentation.

Why it matters

Empty capsules, primarily gelatin-based and vegetarian alternatives, serve as essential components for delivering active ingredients in oral solid dosage forms. Procurement decisions are increasingly guided by strict quality standards, as manufacturers prioritize capsule suppliers capable of delivering consistent shell performance across long replenishment cycles, particularly in high-volume pharmaceutical operations.

The details

Gelatin-based capsules continue to dominate the product type category, holding a 61.8% share, due to their established process familiarity and validated performance in manufacturing environments. Vegetarian-based capsules remain relevant for companies seeking portfolio diversification and alignment with consumer preferences. By raw material, Type-A gelatin leads with a 30.5% share, followed by other options including Type-B gelatin, fish bone gelatin, starch materials, and pullulan. Size '0' empty capsules are the most widely used, accounting for 38.6% of the market, as they align well with standardized dosing formats and existing production setups. Oral delivery overwhelmingly preferred at 88.3%, driven by the scale and repeatability of oral solid dosage programs, with pharmaceutical companies leading the end-user segment at 61.9%.

• The global empty capsules market is expected to grow from $3.22 billion in 2026 to $6.96 billion by 2036.